Kanbe Katsuaki, Chiba Junji, Inoue Yasuo, Taguchi Masashi, Yabuki Akiko
a Department of Orthopaedic Surgery , Tokyo Women's Medical University, Medical Center East , Arakawa , Tokyo , Japan.
Mod Rheumatol. 2016;26(1):46-50. doi: 10.3109/14397595.2015.1054088. Epub 2015 Nov 7.
The aim of this study was to determine whether the levels of stromal cell-derived factor (SDF)-1 and its receptor C-X-C chemokine receptor 4 (CXCR4) in synovium were correlated with clinical outcome and bone and joint destruction in rheumatoid arthritis (RA) patients being treated with golimumab.
Synovial tissues were obtained from 15 golimumab-treated patients and were assessed for SDF-1 and CXCR4 using a new immunohistological scoring system (IH score). The IH score was used to assess correlations between synovial SDF-1 or CXCR4 and the disease activity score (DAS28 CRP), Rooney score, tumor necrosis factor alpha, interleukin-6 (IL-6), CD4, CD20, CD68 and the Assessment of RA by Scoring of Large-Joint Destruction and Healing in Radiographic Imaging (ARASHI) score. Receiver-operating characteristic (ROC) curves were used to predict ARASHI scores from the CXCR4 IH scores.
SDF-1 strongly correlated with the DAS28 CRP and serum IL-6. CXCR4 correlated with synovial CD4 and the ARASHI score. ROC analysis of CXCR4 and ARASHI scores >10 indicated a cutoff of 12 points on the IH score for predicting joint destruction during treatment.
Synovial SDF-1 correlated with disease activity, and its receptor CXCR4 was related to joint destruction in RA patients treated with golimumab.
本研究旨在确定接受戈利木单抗治疗的类风湿关节炎（RA）患者滑膜中基质细胞衍生因子（SDF）-1及其受体C-X-C趋化因子受体4（CXCR4）的水平是否与临床结局以及骨和关节破坏相关。
从15例接受戈利木单抗治疗的患者中获取滑膜组织，并使用一种新的免疫组织学评分系统（IH评分）评估SDF-1和CXCR4。IH评分用于评估滑膜SDF-1或CXCR4与疾病活动评分（DAS28 CRP）、鲁尼评分、肿瘤坏死因子α、白细胞介素-6（IL-6）、CD4、CD20、CD68以及通过影像学评分评估RA的大关节破坏与愈合情况（ARASHI）评分之间的相关性。采用受试者操作特征（ROC）曲线根据CXCR4的IH评分预测ARASHI评分。
SDF-1与DAS28 CRP和血清IL-6密切相关。CXCR4与滑膜CD4和ARASHI评分相关。对CXCR4和ARASHI评分>10进行ROC分析表明，IH评分12分可作为预测治疗期间关节破坏的临界值。
在接受戈利木单抗治疗的RA患者中，滑膜SDF-1与疾病活动相关，其受体CXCR4与关节破坏有关。
